1. **NEW NORDISK $NVO+0.0% ATTRACTIVE GROWTH INVESTMENT**
- Novo Nordisk is a Danish pharmaceutical company with excellent financial growth. -
It is currently attracting the attention of growth investors in the market.
2. **Key factors for investors:**
- Earnings growth: Historically, the company has earnings per share (EPS) growth of 13.5%, with expected growth for this year of up to 18.4%.
- Asset utilization ratio: Novo Nordisk's sales to total assets (S/TA) ratio is 0.79, indicating efficient business operations.
3. **Zacks Rank and Growth Style Score:**
- The company has received significant rankings Zacks Rank (Strong Buy) and in the Zacks Growth Style Score, indicating excellent growth prospects.
4. **Revenue growth and favorable estimate adjustments:**
- Novo Nordisk expects sales growth of 18.7% this year, above the industry average of 3.9%.
- The trend of upward revisions to earnings estimates supports the positive outlook.
5. **Attractive investment opportunity for growth investors:**
- Overall ,$NVO+0.0% is considered an attractive growth investment with future prospects and attracts investors looking for growth potential.
How do you investors like the company?